LENEXA, Kan., July 31, 2024 /PRNewswire/ -- ELIAS Animal Health, a clinical stage development company advancing novel treatments for cancer in companion animals, has initiated a new study evaluating the company’s adoptive T cell therapy—the ELIAS Cancer Immunotherapy (ECI®)—in combination with a novel adjuvant as a limb-sparing treatment for large-breed dogs suffering from appendicular osteosarcoma. The study, which is funded by a grant from Morris Animal Foundation, will be conducted in collaboration with Dr. Jeffrey Bryan and Dr. Megan Mickelson at the University of Missouri. “For dogs with appendicular osteosarcoma, amputation of the affected limb followed by chemotherapy is the typical standard of care. However, in certain cases amputation may not be appropriate,” said ELIAS Chief Medical Officer Noe Reyes, DVM. “In this study, we’re evaluating a new approach where the dog is treated with the limb-sparing surgery followed by ECI® immunotherapy.” The study will assess the safety and efficacy [...]